General Sessions 

Keynote | Wednesday, May 10, 3:15 - 4:30 p.m. CT

Holler if You Hear Me! 
Join us for our keynote presentation with Henry Hicks, President and CEO of the National Museum of African American Music (NMAAM), to explore the origins and enduring impact of Hip Hop, the #1 musical genre in the world today. Fifty years ago, Hip Hop emerged as a powerful new art form and a cry to be heard from previously muted voices. This presentation will explore the vision, skill, tenacity, failures, resets, engagement, independence, collaboration and alliances that drove Hip Hop's success. Just as Hip Hop amplified the voices of marginalized communities and gave voice to important issues, we too can draw on its example to foster greater engagement and integration of patient voices while collaborating to strive for excellence in medication use quality.


General Session | Thursday, May 11,  9:30 - 10:45 a.m. CT 

Navigating the Future of Medicare Part C & D Quality Programs 
Recent program changes to Medicare Part C & D pose the question how can health plans and stakeholders navigate them in 2023 and beyond? Near and long-term implications of recent changes across CMS’ quality programs will be discussed. Panelists will share how they and their partners are responding to changing methodologies to ensure patients receive high-quality care.


General Session | Thursday, May 11,  3:30 - 4:45 p.m. CT 

Exploring Solutions to Improve Equity in Medication Use Quality
The session will explore solutions to reduce medication use quality disparities in a variety of populations. Considering the proposed health equity index and risk adjustment models outlined in the recent CMS rule (CMS 4201-F), our experts will discuss how our healthcare system is improving care for people with certain social risk factors across diverse populations.


Closing General Session | Friday, May 12,  10:15 - 11:30 a.m. CT 
Implications of the Inflation Reduction Act on Medication Access and Affordability
Multiple provisions of the Inflation Reduction Act (IRA) will affect patients’ ability to access medications at an affordable price. This session will begin with an expert presentation on the IRA’s medication cost-related provisions. A panel discussion will follow on the implications of these provisions for various healthcare sectors and include a patient perspective on medication access and how cost reductions could affect them.